Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization

Date
2020
Author
Newell, Amy Hanlon
Menzl, Ina
Penault-Llorca, Frederique
Rossi, Giulio
Pate, Greg
Thunnissen, Erik
Huang, Richard S. P.
Smith, Derek
Le, Catherine H.
Liu, Wen-Wei
Manohar, Chitra
Ordinario, Ellen
Lee, Michael
Rajamani, Jaya
Truong, Huan
Li, Jing
Choi, Cindy
Li, Jingchuan
Pati, Amrita
Bubendorf, Lukas
Buettner, Reinhard
Kerr, Keith M.
Lopez-Rios, Fernando
Marchetti, Antonio
Marondel, Ivonne
Nicholson, Andrew G.
Oz, Aysim Buge
Pauwels, Patrick
Metadata
Show full item record
Abstract
Context.-The ability to determine ROS1 status has become mandatory for patients with lung adenocarcinoma, as many global authorities have approved crizotinib for patients with ROS1-positive lung adenocarcinoma.
URI
http://hdl.handle.net/20.500.12627/4763
https://doi.org/10.5858/arpa.2019-0085-oa
Collections